Format

Send to

Choose Destination
Curr Opin Pharmacol. 2004 Aug;4(4):386-91.

Inhibition of IL-6 for the treatment of inflammatory diseases.

Author information

1
Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-oka, Suita-City, Osaka, 565-0871, Japan. norihiro@fbs.osaka-u.ac.jp

Abstract

Interleukin-6 (IL-6) is a pleiotropic cytokine with various biological activities. Deregulated overproduction of IL-6 has been found to play pathological roles in chronic inflammatory diseases such as rheumatoid arthritis, Castleman's disease, juvenile idiopathic arthritis and Crohn's disease. Humanized anti-IL-6 receptor antibody has been developed as a therapeutic agent for these diseases, and therapeutic benefits have been revealed in clinical studies.

PMID:
15251133
DOI:
10.1016/j.coph.2004.03.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center